Literature DB >> 24882266

Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders.

Payman Shahabi1, Gérard Siest2, Urs A Meyer3, Sophie Visvikis-Siest4.   

Abstract

Beyond their contribution to the metabolism of xenobiotics, cytochrome P450 (CYP) epoxygenases are actively involved in the metabolism of endogenous substances, like arachidonic acid (AA). The main human CYP epoxygenases, i.e. CYP2C8, CYP2C9, CYP2C19 and CYP2J2, convert AA to four regioisomer epoxyeicosatrienoic acids (EETs). EETs possess a wide range of established protective effects on the human cardiovascular system of which anti-inflammatory actions have gained great recent interest. The expression of CYP epoxygenases is regulated through an extremely complex network of nuclear receptors, microRNAs and genetic/epigenetic factors. Accordingly, a large number of biological variables as well as xenobiotics and environmental factors can influence the expression of CYP epoxygenases, resulting in a significant intra- and inter-individual variability in the expression and activity of these enzymes and subsequently in EET biosynthesis. Moreover, human CYP epoxygenases are mainly expressed in the liver; however, these enzymes are also expressed, at various extents, in most extrahepatic tissues, resulting in a marked inter-tissue variability in the expression of CYP epoxygenases. The inter-tissue, inter- and intra-individual variability in the expression of epoxygenases may lead to differences in the relative abundance of EETs among tissues, among individuals of a population and/or different ethnicities and in a given individual under various conditions. The variation in the abundance of EETs may explain, at least in part, the inter-tissue and inter-individual differences observed in the prevalence of inflammation-related disorders including cardiovascular disease, and why in a given individual, various conditions can contribute to the development of diseases with an important inflammatory component.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytochrome P450; Epoxyeicosatrienoic acids; Epoxygenase; Inflammation; Variability

Mesh:

Substances:

Year:  2014        PMID: 24882266     DOI: 10.1016/j.pharmthera.2014.05.011

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  30 in total

1.  Cytokine and inflammatory mediator effects on TRPV4 function in choroid plexus epithelial cells.

Authors:  Stefanie Simpson; Daniel Preston; Christian Schwerk; Horst Schroten; Bonnie Blazer-Yost
Journal:  Am J Physiol Cell Physiol       Date:  2019-08-14       Impact factor: 4.249

Review 2.  Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury.

Authors:  Sukumaran Sanjay; Chandrashekaran Girish
Journal:  Eur J Clin Pharmacol       Date:  2016-12-27       Impact factor: 2.953

3.  Cytochrome P450 (CYP) epoxygenases as potential targets in the management of impaired diabetic wound healing.

Authors:  Huichen Zhao; Jicui Chen; Jiachao Chai; Yuchao Zhang; Cong Yu; Zhe Pan; Peng Gao; Chen Zong; Qingbo Guan; Yuqin Fu; Yuantao Liu
Journal:  Lab Invest       Date:  2017-03-20       Impact factor: 5.662

4.  Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children.

Authors:  Sara Bonafini; Angela Tagetti; Rossella Gaudino; Paolo Cavarzere; Martina Montagnana; Elisa Danese; Marco Benati; Diego Alberto Ramaroli; Sara Raimondi; Alice Giontella; Anna Mantovani; Angela Donato; Andrea Dalbeni; Pietro Minuz; Franco Antoniazzi; Claudio Maffeis; Cristiano Fava
Journal:  Eur J Nutr       Date:  2018-03-28       Impact factor: 5.614

Review 5.  Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.

Authors:  Melissa Gabbs; Shan Leng; Jessay G Devassy; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

Review 6.  Role of oxylipins in cardiovascular diseases.

Authors:  Mohammed A Nayeem
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

7.  The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.

Authors:  Lindsay N Sausville; Mahesha H Gangadhariah; Manuel Chiusa; Shaojun Mei; Shouzuo Wei; Roy Zent; James M Luther; Megan M Shuey; Jorge H Capdevila; John R Falck; F Peter Guengerich; Scott M Williams; Ambra Pozzi
Journal:  Cancer Res       Date:  2018-07-16       Impact factor: 12.701

Review 8.  20-HETE in the regulation of vascular and cardiac function.

Authors:  Petra Rocic; Michal Laniado Schwartzman
Journal:  Pharmacol Ther       Date:  2018-07-23       Impact factor: 12.310

9.  Macrophage epoxygenase determines a profibrotic transcriptome signature.

Authors:  Ana Garcia Diaz; Lara Venda; Jeong-Hun Ko; Jacques Behmoaras; Prashant Srivastava; Alex Montoya; Peter Faull; Zoe Webster; Ben Moyon; Charles D Pusey; David J Abraham; Enrico Petretto; Terence H Cook; Timothy J Aitman
Journal:  J Immunol       Date:  2015-04-03       Impact factor: 5.422

10.  Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.

Authors:  Abdurrahman Dolunay; Sefika Pinar Senol; Meryem Temiz-Resitoglu; Demet Sinem Guden; Ayse Nihal Sari; Seyhan Sahan-Firat; Bahar Tunctan
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.